Bidridistrogene xeboparvovec (SRP-9003) demonstrated a favorable safety profile over 4-5 years in a phase 1/2 trial for limb-girdle muscular dystrophy 2E/R4, with most treatment-related adverse events occurring within 90 days post-infusion.
Sarepta Therapeutics has finished dosing in the Phase III EMERGENE trial of SRP-9003, a gene therapy for limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4).
Sarepta Therapeutics reported a significant increase in total revenues for Q3 2024, reaching $1,243.6 million, up from $846.6 million in the same period last year.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.